Announcements Trials
Browse Landscape

Phase

Phase 1 11Phase 2 8Phase 1/2 3Phase 3 2Phase NA 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3

Conditions

Multiple Myeloma 9Recurrence 5Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myeloid, Acute 3Sarcoma 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Waldenstrom Macroglobulinemia 1Vascular Neoplasms 1Triple Negative Breast Neoplasms 1Solitary Fibrous Tumors 1Solid Tumor Malignancy 1Smooth Muscle Tumor 1Sarcoma, Clear Cell 1Recurrent Squamous Cell Lung Carcinoma 1Pancreatic Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1Nerve Sheath Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms, Adipose Tissue 1Neoplasm Metastasis 1Myoepithelioma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Liposarcoma, Myxoid 1Liposarcoma 1

Interventions

Cytarabine 81Azacitidine 66venetoclax 55fludarabine 34fludarabine phosphate 31Decitabine 28Cyclophosphamide 28Idarubicin 24Peripheral Blood Stem Cell Transplantation 22Filgrastim 20Granulocyte Colony-Stimulating Factor 18Busulfan 18Mitoxantrone 16Etoposide 16Whole-Body Irradiation 15Mycophenolic Acid 14Cyclosporine 14Tacrolimus 13Melphalan 13Daunorubicin 13Clofarabine 13Methotrexate 12gilteritinib 11aldesleukin 11plerixafor 10Injections 10decitabine and cedazuridine drug combination 9Gemtuzumab 9Cladribine 9quizartinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Myeloid, Acute × selinexor × Clear all
NCT06449482 2025-05-30

Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy

Institute of Hematology & Blood Diseases Hospital, China

Phase 1/2 Terminated
6 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02530476 2020-03-31

Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Completed
17 enrolled 14 charts
Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02416908 2020-03-13

Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia

Washington University School of Medicine

Phase 1/2 Completed
40 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡